Is Agilent Technologies, Inc. overvalued or undervalued?

As of 7 July 2025, Agilent Technologies, Inc. has moved from expensive to fair in its valuation grade, indicating a more favorable assessment. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. shows an even steeper P/E of 53.65, suggesting that Agilent is relatively more attractive within its industry.
Despite the fair valuation, Agilent's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -5.00% compared to the index's 12.22%. Over the past five years, Agilent's return of 28.42% is significantly lower than the S&P 500's impressive 96.61%, highlighting a potential opportunity for investors looking for value in the pharmaceuticals and biotechnology sector.